about
Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppressionPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisAdvances in cholangiocyte immunobiologyTargeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cellsSynergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadeStructure and Interactions of the Human Programmed Cell Death 1 ReceptorSafety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerA fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumorsEvaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelTarget-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerancePartial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.VISTA is an immune checkpoint molecule for human T cells.Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patientsPD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice.PD-L1 expression is increased in a subset of basal type breast cancer cells.The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivoPD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.Multiple layers of CD80/86-dependent costimulatory activity regulate primary, memory, and secondary lymphocytic choriomeningitis virus-specific T cell immunityNovel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.PD-L1 expression and prognostic impact in glioblastoma.NKT cell costimulation: experimental progress and therapeutic promisePD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1The complex role of B7 molecules in tumor immunologyCostimulation Blockade in Kidney Transplantation: An UpdateProgrammed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.Targeting lymphocyte co-stimulation: from bench to bedside.Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker.CD28-specific immunomodulating antibodies: what can be learned from experimental models?MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.
P2860
Q21089831-2EC9E7E7-D6C8-46E2-A952-5F4929D74D74Q26769728-62AA83D7-4D01-4908-9AA6-9BE733240AA6Q27002954-7F505D52-46F8-40B4-822B-D3DF8C25D5FEQ27340853-20862307-B101-4719-9211-0E0EB8609894Q27487939-78DB8432-D98A-4A59-9355-2DE2FEF4B98FQ27676419-852D580C-B9D2-40A0-8D05-6C22BA73FFDAQ27860857-F1EBCA0C-2362-484C-B9A8-9D1FAD476335Q28510246-948726D2-59E4-4D5E-A6C2-2B2B5B7A3DA8Q31137039-5F07FDBD-75CB-4DE4-85AC-64621B46AACCQ33573593-43423A19-6351-4AB6-AB4A-16602851ABC5Q33728672-6D152ECC-8BEE-4822-A7C8-AF7CDBBEBCBAQ34018474-E105A633-37EE-42B3-98A2-5B7D8DC53CD0Q34024724-18004670-B9FD-4628-821A-8B066E95881BQ34122678-AED3A4D8-8EE6-4950-BAB3-FC22BB84E466Q34137984-BD682278-C994-4D40-926F-8F454E0B2AC3Q34154994-A7E5C9C9-7943-4B6F-89D7-55A8F192F1F3Q34298906-4FF576AA-2EEB-417A-9FD4-2861E662FAA0Q34413221-B606119E-C2AB-411C-8B4A-980E8865F58CQ34984010-D7A8EE86-D43D-480A-963B-20B33374C55DQ35004384-9828AD1B-96EF-4921-BF68-503C37B661C6Q35097436-D08F53B9-0785-4836-B285-0E8BD91BC75FQ35140721-F9A65B72-66C4-43D5-89E3-F5E44217E825Q35201893-D2B6A43B-FB27-41EA-B2CF-B629CA2B2A80Q35364931-ECC109BF-5201-4D8C-A3AA-1D488ACDF1D9Q35826538-F74E04CF-8154-49C3-9141-AF75419FAC09Q36021225-CABC7922-AA7A-4AFA-8B83-824864C068A0Q36039709-73E31348-A02D-47F4-AE12-FB4377180EC3Q36067682-0BC04332-8864-4898-8223-255B22EE8D33Q36493843-16AFF80F-F088-491E-A158-B5274C04356FQ36739843-9B2ADE70-2FDC-4207-B3C5-8C5F20B8CAEFQ36882550-E989BBB5-B1F2-4B81-A4E9-E74774C4E3F9Q36939402-E0830192-B435-419F-9B32-0165EBFDB585Q37249892-C479DB42-924A-49D3-92CD-01DB87878A0AQ37304913-FCF68C1E-FF9B-4360-A8F9-0335FD468AB5Q37375148-269D1126-2DC2-4159-B7A1-C7DE88F224C8Q37691082-11AA5641-2A53-4D3E-88A4-8B1A0A637DF2Q37739486-3875C602-D9EA-478C-AF15-13AE3C6BAEA5Q37793216-06AC5AF7-5F13-4200-A768-412B35EC27DAQ37999397-92C14724-4D76-438C-9E0D-3E731C743DBBQ38040302-E80F7E8D-B585-44F8-9942-D0F6966B8461
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Interaction of human PD-L1 and B7-1.
@ast
Interaction of human PD-L1 and B7-1.
@en
Interaction of human PD-L1 and B7-1.
@nl
type
label
Interaction of human PD-L1 and B7-1.
@ast
Interaction of human PD-L1 and B7-1.
@en
Interaction of human PD-L1 and B7-1.
@nl
prefLabel
Interaction of human PD-L1 and B7-1.
@ast
Interaction of human PD-L1 and B7-1.
@en
Interaction of human PD-L1 and B7-1.
@nl
P2093
P2860
P1433
P1476
Interaction of human PD-L1 and B7-1.
@en
P2093
Arlene H Sharpe
Gordon J Freeman
Mi-Jung Kim
Victor Peña-Cruz
P2860
P304
P356
10.1016/J.MOLIMM.2008.05.014
P577
2008-06-27T00:00:00Z